Drug like HSP27 cross linkers with chromenone structure ameliorates pulmonary fibrosis
Background: Pulmonary fibrosis (PF) is a progressive lung disease characterized by fibroblast accumulation and collagen deposition, resulting in lung scarring and impaired gas exchange. Current treatments for idiopathic pulmonary fibrosis (IPF) have limited efficacy and significant side effects. Hea...
Main Authors: | Young Jo Yoo, Seulgi Jeon, Hee Jin, Hee Yeon Won, Mi Gyeong Jeong, Yeseul Cho, Eun Sook Hwang, Younghwa Na, Jaeho Cho, Yun-Sil Lee |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-07-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1203033/full |
Similar Items
-
Drug-Like Small Molecule HSP27 Functional Inhibitor Sensitizes Lung Cancer Cells to Gefitinib or Cisplatin by Inducing Altered Cross-Linked Hsp27 Dimers
by: Hawon Yoo, et al.
Published: (2021-04-01) -
The miR-15b-Smurf2-HSP27 axis promotes pulmonary fibrosis
by: Seulgi Jeon, et al.
Published: (2023-01-01) -
Specific Roles of HSP27 S15 Phosphorylation Augmenting the Nuclear Function of HER2 to Promote Trastuzumab Resistance
by: Soo-Yeon Hwang, et al.
Published: (2020-06-01) -
The Role of Hsp27 in Chemotherapy Resistance
by: Marios Lampros, et al.
Published: (2022-04-01) -
On I. Meghea and C. S. Stamin review article “Remarks on some variants of minimal point theorem and Ekeland variational principle with applications,” Demonstratio Mathematica 2022; 55: 354–379
by: Göpfert Alfred, et al.
Published: (2023-10-01)